moxifloxacin
moxifloxacin: sourced relationships with 1 company · 16 clinical trials tracked · 1 FDA decision.
moxifloxacin evidence translation
What we can confirm
1 FDA record · 16 tracked trials
What it means
What to watch
Prepared research question
How could moxifloxacin → RDY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 9 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) Reported 2014-03-04 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (16)showing 10 most recent
A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
Primary endpoint: The primary outcome of the Intervention Program is microbiological clearance of Mycobacterium abscessus (MABS) with good tolerance of the interventions.
A Phase 1, Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization in Healthy Participants
Primary endpoint: Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)
A Phase 1, Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Positive-controlled, 4-period Crossover Study to Evaluate the Effect of a Single Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
Primary endpoint: Change from baseline in the QT interval corrected using the Fridericia formula (QTcF) centrally assessed using a semi-automatic reading
A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, Parallel Group Study With Nested Crossover Comparison to Assess the Effect of Maridebart Cafraglutide on QT/QTc Intervals in Participants Living With Overweight or Obesity
Primary endpoint: Change from Baseline in QTcF for Maridebart Cafraglutide
A Study to Assess the Effect of Etavopivat on Cardiac Repolarisation in Healthy Participants
Primary endpoint: Part A: Number of treatment-emergent adverse events (AEs)
A Phase 1, Randomized, Single-Dose, Positive- and Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effects of Varegacestat on Cardiac Repolarization in Healthy Participants
Primary endpoint: Placebo-corrected change from baseline QTc and varegacestat and its metabolite, AL102 MTB, plasma concentrations
Shortened Regimen for Drug-susceptible TB in Children
Primary endpoint: TB disease-free survival at 48-weeks
Phase 1, Randomized, Double-Blind Four-Period Crossover, Thorough QT/QTc Study to Evaluate the Effects of EDP-938 on Cardiac Repolarization in Healthy Adults
Primary endpoint: Time-matched, placebo-corrected change-from-baseline QTc based on the Fridericia correction QTcF (ΔΔQTcF) after TD and SD of Zelicapavir
A Phase 1, Partially Blinded, Randomized, Crossover Study to Evaluate the Pharmacokinetics and QT/QTc Interval of ESK-001 Compared to Placebo and Moxifloxacin in Healthy Subjects
Primary endpoint: Change from baseline in placebo-adjusted QTcF (∆∆QTcF)
A Phase 1, Double-Blinded, Placebo- and Active-Controlled, Randomized Study to Investigate the Potential of Soticlestat to Prolong the QTc Interval in Healthy Adult Participants
Primary endpoint: Placebo-corrected Change From Baseline in Corrected QT Interval (QTc)
Frequently asked questions
Which companies have sourced relationships with moxifloxacin?
moxifloxacin has dated SEC/FDA relationship records for DR REDDYS LABORATORIES LTD.
How many clinical trials involve moxifloxacin?
BioSniper tracks 16 clinical trials involving moxifloxacin.
What is moxifloxacin's latest FDA decision?
The most recent tracked FDA decision for moxifloxacin is Approval, dated March 4, 2014.